FIELD: medicine; pharmaceuticals.
SUBSTANCE: invention relates to novel compounds of formula I, as well as pharmaceutical compositions based thereon.
(formula I)
EFFECT: obtaining novel compounds suitable for treating RORγ-mediated diseases or conditions, such as rheumatoid arthritis, psoriasis, inflammatory bowel disease, Crohn's disease and multiple sclerosis.
12 cl, 39 ex
Title | Year | Author | Number |
---|---|---|---|
ROR GAMMA MODULATORS (RORγ) | 2016 |
|
RU2735546C2 |
ROR GAMMA (RORγ) MODULATORS | 2016 |
|
RU2727698C2 |
ROR GAMMA (RORγ) MODULATORS | 2016 |
|
RU2730454C2 |
ROR GAMMA (RORγ) MODULATORS | 2016 |
|
RU2727191C2 |
GLUCOCORTICOID RECEPTOR NON-STEROID MODULATORS | 2006 |
|
RU2409577C2 |
NONSTEROID COMPOUNDS EFFECTIVE AS GLUCOCORTICOID RECEPTOR MODULATORS | 2006 |
|
RU2420528C2 |
ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS | 2011 |
|
RU2535671C1 |
NEW ISOXAZOLIL ETHER DERIVATIVES AS PAM GABA A ALFA5 | 2019 |
|
RU2800160C2 |
NOVEL CYCLOHEXANE DERIVATIVES | 2005 |
|
RU2382029C2 |
BENZIMIDAZOLE DERIVATIVES AS ROR-GAMMA MODULATORS | 2017 |
|
RU2760366C2 |
Authors
Dates
2020-10-01—Published
2016-06-03—Filed